Viking Therapeutics, Inc. (NASDAQ:VKTX)
| Market Cap | 3.44B-27.7% |
| Revenue (ttm) | 0 |
| Net Income | -627.20M-164.2% |
| EPS | -5.40-154.7% |
| Shares Out | 127.52M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,064,574 |
| Open | 25.96 |
| Previous Close | 25.79 |
| Day's Range | 25.57 - 27.02 |
| 52-Week Range | 23.82 - 43.15 |
| Beta | 0.65 |
| Analysts | Buy |
| Price Target | 82.00(+204.38%) |
| Earnings Date | Feb 10, 2027 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About VKTX
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating VKTX in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 10, 2027Earnings report
Ask Barron about VKTX
$VKTX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in VKTX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by VKTX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
VKTX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New VKTX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to VKTX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in VKTX
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $122.38M |
| XBIState Street SPDR S&P Biotech ETF | $91.91M |
| VBVanguard Morningstar Small-Cap ETF | $86.74M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $48.34M |
| VXFVanguard Extended Market ETF | $45.75M |
| SCHASchwab U.S. Small-Cap ETF | $17.10M |
Estimated from each fund’s disclosed top holdings × AUM
VKTX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from VKTX’s recent data — informational, not investment advice
What’s Behind the Score
News check: UBS initiated bullish coverage with $94 target and Buy rating; Q3 earnings miss offset by positive obesity pipeline progress and analyst confidence in 2029 launch timeline.